FORTEO
Generic Name for FORTEO
Teriparatide (recombinant) 250micrograms/mL; soln for SC inj; contains m-cresol.
Legal Classification:
Rx
Pharmacological Class for FORTEO
Hormone (human parathyroid hormone, recombinant).
Manufacturer of FORTEO
Lilly, Eli and Company
|
Indications for FORTEO
Postmenopausal osteoporosis in women who are at high risk for fracture. To increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. Treatment of men and women with osteoporosis associated with sustained glucocorticoid therapy at high risk for fracture (see literature).
Adult dose for FORTEO
20 micrograms SC once daily into thigh or abdominal wall; may treat for up to 2 years.
Children's dosing for FORTEO
Not recommended.
Precautions for FORTEO
Increased baseline risk for osteosarcoma (eg, Paget's disease of bone, unexplained increased alkaline phosphatase, open epiphyses, prior skeletal radiation therapy), bone metastases, history of skeletal malignancies, metabolic bone disease, hypercalcemia or risk thereof (eg, hyperparathyroidism): not recommended. Urolithiasis. Hypercalciuria. Hepatic, renal, or cardiac disease. Pregnancy (Cat.C). Nursing mothers: not recommended.
Interactions for FORTEO
Caution with digoxin (teriparatide-induced hypercalcemia increases risk of toxicity).
Adverse Reactions for FORTEO
Arthralgia, pain, nausea; transient orthostatic hypotension, hypercalcemia, hyperuricemia, inj site reactions.
How is FORTEO supplied?
Multidose Pen (2.4mL, 3mL)—1
Related Disease:
Bone disorders
Osteoporosis~bone metabolism